Joint Analyst Price Targets - Benzinga

The Joint Corp

JYNTNASDAQ

Trade with Public

Trade with Public

$8.43

0.020.24%

가까이에: Aug 28, 5:00 PM EST

$8.59

0.161.9%

시간외: 5:06 PM EST

개요 뉴스 실적 전망 이벤트목표가재무 심리 지분 현황 비교 옵션 주식 보고서

Joint Analyst Price Targets

Wall Street analyst price targets and consensus rating for Joint (JYNT).

Price Target Range — 6 Quarters

Analyst Consensus — 3 Analysts

3Buy

Consensus RatingBuy# Analysts3Avg. Consensus PT$17Upside to Avg. PT+100.8%

Rating Trend — Last 9 Months

Recent Analyst Actions

View all ratings →

Date	Firm	Analyst	Action	Rating Change	Price Target
Aug 8, 2025	B. Riley Securities	Jeff Van Sinderen	PT Cut	Buy	$20→$18
May 9, 2025	Lake Street	Ryan Meyers	PT Cut	Buy	$20→$16
Nov 8, 2024	Roth MKM	George Kelly	PT Cut	Buy	$16→$15
Aug 9, 2024	Lake Street	Brooks O'Neil	PT Raise	Buy	$15→$20
May 6, 2024	B. Riley Securities	Jeff Van Sinderen	PT Raise	Buy	$12→$20
May 3, 2024	Roth MKM	George Kelly	PT Raise	Buy	$13→$16
Sep 14, 2023	Roth MKM	George Kelly	PT Cut	Buy	$16→$13

More with Benzinga EdgeGet Access

Analyst Ratings News

PRO
B. Riley Securities Maintains Buy on Joint, Lowers Price Target to $18

B. Riley Securities analyst Jeff Van Sinderen maintains Joint (NASDAQ:JYNT) with a Buy and lowers the price target from $20 to $18.

Benzinga Newsdesk

PRO
Lake Street Maintains Buy on Joint, Lowers Price Target to $16

Lake Street analyst Ryan Meyers maintains Joint (NASDAQ:JYNT) with a Buy and lowers the price target from $20 to $16.

Benzinga Newsdesk

PRO
Roth MKM Maintains Buy on Joint, Lowers Price Target to $15

Roth MKM analyst George Kelly maintains Joint (NASDAQ:JYNT) with a Buy and lowers the price target from $16 to $15.

Benzinga Newsdesk

Quest Diagnostics to Expand in Canada With LifeLabs Buyout

Quest Diagnostics (NYSE: DGX) has entered into a definitive agreement with OMERS to acquire LifeLabs, a prominent Canadian provider of community laboratory tests.

Zacks

Neuronetics Expands NeuroStar Portfolio With New Launch

Neuronetics, Inc. (NASDAQ: STIM) recently announced the nationwide launch of the Better Me Provider (BMP) program. The BMP program will be a part of the company's NeuroStar product line.

Zacks

PRO
B. Riley Securities Maintains Buy on Joint, Raises Price Target to $20

B. Riley Securities analyst Jeff Van Sinderen maintains Joint (NASDAQ:JYNT) with a Buy and raises the price target from $12 to $20.

Benzinga Newsdesk